<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244451</url>
  </required_header>
  <id_info>
    <org_study_id>CLL0809</org_study_id>
    <nct_id>NCT01244451</nct_id>
  </id_info>
  <brief_title>GIMEMA CLL0809 Study (BendOfa)</brief_title>
  <acronym>BendOfa</acronym>
  <official_title>A Single-Arm Multi-Center Trial of Bendamustine Given With Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL). EudraCT Number 2009-017663-42. GIMEMA CLL0809 Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last ten years there have been significant developments in CLL treatment. The advent
      of fludarabine, rituximab and the association of chemo-immunotherapy have substantially
      increased overall response rate, CR rate, time to progression and may also have an impact on
      overall survival.

      Even though, CLL remains incurable and all patients eventually relapse and progressively
      become resistant to treatment. The development of an effective therapy that is not
      cross-resistant with the ones currently available as front-line treatment, is one of the
      clinical unmet needs within CLL.

      BendOfa is a non comparative phase II trial designed to determine the therapeutic benefit of
      bendamustine given together to ofatumumab in relapsed or resistant patients with CLL.

      Bendamustine is approved by FDA for CLL treatment, it is an hybrid drug with alkylating
      agents and purine analogue properties that may lack of cross resistance with fludarabine. It
      was utilized in CLL as a single agent and its association with rituximab is currently under
      clinical investigation.

      Ofatumumab is a new fully human anti-CD20 monoclonal antibody with high in vitro efficacy on
      CD20 low-expressing CLL cells. An early report showed that ofatumumab in single therapy is
      effective in highly pre-treated refractory CLL patients.

      Both drugs were generally well tolerated without unexpected untoward toxicity. On the basis
      of these data, bendamustine and ofatumumab could be a new effective and well tolerated
      combination for patients with relapsed and refractory CLL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Contributing to the Overall Response Rate</measure>
    <time_frame>After 8 months from therapy start (6 months of treatment plus 2 months from the last course to response evaluation)</time_frame>
    <description>Patients response to treatment will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity According to CTCAE Version 4.0</measure>
    <time_frame>At 44 months from treatment start.</time_frame>
    <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 32 months: from the date of first BendOfa treatment dose - induction phase - until the date of the first documentation of progressive disease or until death (whatever the cause), whichever occurs first.</time_frame>
    <description>Patients still alive and known to be progression-free will be censored at the moment of last follow-up. Patients disease progression will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 44 months from treatment start.</time_frame>
    <description>Patients still alive will be censored at the moment of last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or</condition>
  <condition>Patients With CLL Refractory (SD, PD or CR/PR &lt; 6 Months) Following no More Than Two Prior Treatment Lines</condition>
  <arm_group>
    <arm_group_label>Bendofa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine + Ofatumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.</description>
    <arm_group_label>Bendofa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.</description>
    <arm_group_label>Bendofa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CLL relapsing after an initial response (CR, PR ≥ 6 months) following no
             more than two prior treatment lines; or

          -  Patients with CLL refractory (SD, PD or CR/PR &lt; 6 months) following no more than two
             prior treatment lines

          -  Patients requiring treatment according to 2008 revised IWCLL guidelines

          -  No more than 2 prior treatment lines

          -  Age older or equal to 18 years

          -  No active malignancies during the previous 5 years, with the exception of currently
             treated basal cell or squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of
             any origin

          -  No prior treatment with conventional chemotherapy within the prior 4 weeks and with
             monoclonal antibodies within the prior 16 weeks

          -  ECOG performance status of ≤2 at study entry

          -  Laboratory test results within these ranges:

        Serum creatinine ≤ 2 x UNL Creatinine clearance ≥ 50 ml/min (Cockcroft and Gault formula)
        Total bilirubin ≤ 2 x UNL (with exception of patients with Gilbert's syndrome) AST (SGOT)
        and ALT (SGPT) ≤ 2 x UNL non attributable to CLL AST (SGOT) and ALT (SGPT) ≤ 10 x UNL
        attributable to CLL

          -  Female subjects of childbearing potential(FCBP) must:

        Understands the potential teratogenic risk to the unborn child and the need for effective
        contraception;

        Be capable of complying with effective contraceptive measures.

        Be informed and understand the potential consequences of pregnancy and the need to notify
        her study doctor immediately if there is a risk of pregnancy.

        Understand the need to commence the study treatment as soon as study drug is dispensed
        following a negative pregnancy test.

        Understand the need and accepts to undergo pregnancy testing based on the frequency
        outlined in this protocol.

        Females of childbearing potential (FCBP) enrolled in this protocol must agree to use two
        reliable forms of contraception simultaneously or to practice complete abstinence from
        heterosexual contact during the following time periods related to this study: 1) before
        starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for
        at least 28 days after study treatment discontinuation.

        The two methods of reliable contraception must include one highly effective method and one
        additional effective (barrier) method. FCBP must be referred to a qualified provider of
        contraceptive methods if needed. The following are examples of highly effective and
        additional effective methods of contraception:

        Highly effective methods:

          -  Intrauterine device (IUD)

          -  Hormonal (birth control pills, injections, implants)

          -  Tubal ligation

          -  Partner's vasectomy

        Additional effective methods:

          -  Male condom

          -  Diaphragm

          -  Cervical Cap

          -  Implants and levonorgestrel-releasing intrauterine systems are associated with an
             increased risk of infection at the time of insertion and irregular vaginal bleeding.
             Prophylactic antibiotics should be considered particularly in patients with
             neutropenia.

          -  Pregnancy testing.

        FCBP must have two negative pregnancy tests prior to starting study drug.

        FCBP must agree to have a medically supervised pregnancy test every 4 weeks including 4
        weeks after the end of study treatment, except in the case of confirmed tubal
        sterilization. This requirement also applies to women of childbearing potential who
        practice complete and continued abstinence.

        Females must agree to abstain from breastfeeding during study participation and for at
        least 28 days after study drug discontinuation.

        - Male patients must:

        Understand the potential teratogenic risk if engaged in sexual activity with a pregnant
        female or a female of childbearing potential.

        Must practice complete abstinence or agree to use a prophylactic during sexual contact with
        a pregnant female or a female of childbearing potential while participating in the study,
        during dose interruptions and for at least 6 months following study drug discontinuation,
        even if he has undergone a successful vasectomy.

        If pregnancy or a positive pregnancy test does occur in the partner of a male study patient
        during study participation, the investigator must be notified immediately.

        - Female and male patients

        should be instructed never to give this medicinal product to another person and to return
        any unused capsules to the study doctor at the end of treatment.

        Should not donate blood during therapy and for at least 28 days following discontinuation
        of study drug.

        Male patients should not donate semen or sperm while participating in the study, during
        dose interruptions and for at least 6 months following study drug discontinuation

          -  Signed written informed consent according to IGH/EU/GCP and Italian laws.

        Exclusion Criteria:

          -  Concurrent use of other anti-cancer agents

          -  Use of any other experimental drug or therapy within 28 days of baseline

          -  Positive direct antiglobulin test (DAT) with clinical and laboratory signs of
             hemolysis and/or autoimmune thrombocytopenia

          -  Known transformation of CLL

          -  Known CNS involvement of CLL

          -  Known positivity for HIV or active HCV and HBV hepatitis.

          -  Active bacterial, viral or fungal infection requiring systemic anti-viral, antibiotic
             or anti-fungal therapy.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Subjects who have current active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones or stable chronic liver
             disease per investigator assessment)

          -  Pregnant or Lactating Females.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she was to participate in the study or confounds
             the ability to interpret data from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agostino Cortelezzi, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Direzione Scientifica - Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento Area Medica - Presidio Ospedaliero &quot;C. e G.Mazzoni&quot;</name>
      <address>
        <city>Ascoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia 1 - Università degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist.Ematologia e Oncologia Medica L.e A. Seragnoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ASL di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>9121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi, Università delgi studi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Università degli Studi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le1 P.O. Vito Fazzi - U.O. di Ematologia</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Messina Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez. di medicina Interna Oncologia ed Ematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <zip>80143</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O. &quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Roma La Cattolica</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SS.C. di Oncoematologia - Dipartimento di Medicina Clinica e Sperimentale - Azienda Ospedaliera - S. Maria Di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia &quot;Molinette&quot; Osp. Maggiore S. G. Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it/en/index.php</url>
    <description>GIMEMA Foundation Website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <results_first_submitted>February 22, 2016</results_first_submitted>
  <results_first_submitted_qc>January 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Ofatumumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bendofa</title>
          <description>Bendamustine + Ofatumumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bendofa</title>
          <description>Bendamustine + Ofatumumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.85" lower_limit="46.12" upper_limit="81.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Contributing to the Overall Response Rate</title>
        <description>Patients response to treatment will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
        <time_frame>After 8 months from therapy start (6 months of treatment plus 2 months from the last course to response evaluation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendofa</title>
            <description>Bendamustine + Ofatumumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Contributing to the Overall Response Rate</title>
          <description>Patients response to treatment will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity According to CTCAE Version 4.0</title>
        <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
        <time_frame>At 44 months from treatment start.</time_frame>
        <population>Number of patients experiencing 3 or &gt;3 Adverse Events (AEs) (both hematological and not hematological)</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity According to CTCAE Version 4.0</title>
          <description>Number of patients experiencing 3 or &gt;3 AEs (both hematological and not hematological)</description>
          <population>Number of patients experiencing 3 or &gt;3 Adverse Events (AEs) (both hematological and not hematological)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Patients still alive and known to be progression-free will be censored at the moment of last follow-up. Patients disease progression will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
        <time_frame>Up to 32 months: from the date of first BendOfa treatment dose - induction phase - until the date of the first documentation of progressive disease or until death (whatever the cause), whichever occurs first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendofa</title>
            <description>Bendamustine + Ofatumumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Patients still alive and known to be progression-free will be censored at the moment of last follow-up. Patients disease progression will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy and radiographic evaluation according to the revised IWCLL 2008 criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Patients still alive will be censored at the moment of last follow-up.</description>
        <time_frame>At 44 months from treatment start.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendofa</title>
            <description>Bendamustine + Ofatumumab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Patients still alive will be censored at the moment of last follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Autoimmune hemolytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Other toxicity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PIs of participating centres may disclose their centre's results only after the main study publication has been released, so that a single centre experience can be compared to the study overall results and give a more appropriate view of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alfonso Piciocchi</name_or_title>
      <organization>GIMEMA</organization>
      <phone>+39 06 70390528</phone>
      <email>a.piciocchi@gimema.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

